期刊文献+

中药联合阿德福韦酯治疗乙型肝炎肝硬化失代偿期疗效观察 被引量:2

下载PDF
导出
摘要 目的:观察中药联合阿德福韦酯治疗乙型肝炎肝硬化失代偿期患者的疗效和安全性。方法:选择肝硬化失代偿期患者62例,随机分为2组,一组用普通保肝对症支持治疗,另一组在保肝对症支持治疗的基础上加用中药鼓胀浓缩胶囊联合阿德福韦酯治疗。结果:治疗6月后治疗组肝功能及凝血功能明显改善,两组间有显著性差异(P〈0.05);HBV-DNA定量、Child-Pugh评分减少明显优于对照组(P〈0.01)。治疗后治疗组在改善患者症状方面,与对照组比较,差异有显著性意义(P〈0.01)。治疗后远期随访12—18月,治疗组肝性脑病、感染、肝肾综合征、腹水复发的发生率及死亡率明显低于对照组,两组比较有显著性差异(P〈0.05)。整个治疗过程中未观察到明显的不良反应。结论:中药联合阿德福韦酯治疗乙肝肝硬化失代偿期患者的疗效肯定,安全性好,可改善乙肝后肝硬化失代偿期患者的肝功能,阻止病情发展,延长患者生存期。
作者 敬小华
出处 《四川中医》 2009年第6期68-69,共2页 Journal of Sichuan of Traditional Chinese Medicine
  • 相关文献

参考文献4

二级参考文献40

  • 1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
  • 2Lock ASF,McMahon BJ.Chronic hepatitis B:update of recommendation.Hepatology,2004,39:857-861.
  • 3Liaw YF,Leung N,Guan R,et al.Asian-Pacific Consensus Working Parties on Hepatitis B.Related Articles,Links Asian-Pacific consensus statement on the management of chronic hepatitis B:an update.J Gastroenterol Hepatol,2003,18:239-245.
  • 4Yim HJ,Lok AS.Natural history of chronic hepatitis B virus infection:what we knew in 1981 and what we know in 2005.Hepatology,2006,43(2 Suppl 1):173-181.
  • 5Perrillo RP.Therapy of hepatitis B-viral suppression or eradication?Hepatology,2006,43(2 Suppl 1):S182-193.
  • 6Zoulim F.New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.J Hepatol,2005,42:302-308.
  • 7Murray JM,Wieland SF,Purcell RH,et al.Dynamics of hepatitis B virus clearance in chimpanzees.Proc Natl Acad Sci U S A,2005,102:17780-17785.
  • 8Locamini S.Molecular virology of hepatitis B virus.Semin Liver Dis,2004,24 (Suppl):3-10.
  • 9Feld J,Lee JY,Locarnini S.New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B.Hepatology,2003,38:545-553.
  • 10Owada T,Matsubayashi K,Sakata H,et al.Interaction between desialylated hepatitis B virus and asialoglycoprotein receptor on hepatocytes may be indispensable for viral binding and entry.J Viral Hepat,2006,13:11-18.

共引文献456

同被引文献31

  • 1LI Man,WANG Zhuo Qun,ZHANG Lu,ZHENG Hao,LIU Dian Wu,ZHOU Mai Geng.Burden of Cirrhosis and Other Chronic Liver Diseases Caused by Specific Etiologies in China, 1990-2016:Findings from the Global Burden of Disease Study 2016[J].Biomedical and Environmental Sciences,2020,33(1):1-10. 被引量:52
  • 2杨柳青,林国莉,吴元凯,李向永,熊庭婷,高志良,崇雨田.乙型肝炎肝硬化患者核苷(酸)类药物治疗期间新发肝癌的危险因素分析[J].中华临床感染病杂志,2012,5(1):28-32. 被引量:4
  • 3慢性乙型肝炎防治指南[J].中华内科杂志,2006,45(2):162-170. 被引量:185
  • 4Zoulim F,Radenne S,Duceff C. Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transpl, 2008,14 Suppl 2:S1-7.
  • 5Lloeje UH,Yang HI,Su J,et al. Predicting cirrhosis risk based the level of circulating hepatitis B viral load. Gastroenterology, 2006, 130( 3 ):678-686.
  • 6Choe WH,Hong SP,Kim BK,et al.Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefoviL Antivir Ther, 2009,14 ( 7 ) :985-993.
  • 7Lok AS,McMahon BJ. Chronic hepatitis B:update 2009. Hepatology, 200 9,50 ( 3 ):661-662.
  • 8European Association for the Study of the Liver. EASL clinical practice guidelines:management of chronic hepatitis B. J Hepatol, 2009,50(2):227-242.
  • 9Liaw YF,Sung JJ,Chow WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351( 15):1521-1531.
  • 10Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates : results after 3 years of therapy. Hepatology, 2001,33 ( 6 ) : 1527-1532.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部